Theravance Biopharma (NASDAQ:TBPH) issued its earnings results on Tuesday. The biopharmaceutical company reported ($1.05) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($1.05), Fidelity Earnings reports. The company had revenue of $12.43 million during the quarter, compared to analysts’ expectations of $13.33 million.
Shares of NASDAQ TBPH traded up $0.12 on Friday, hitting $17.60. The company had a trading volume of 171,461 shares, compared to its average volume of 249,274. Theravance Biopharma has a 12-month low of $15.18 and a 12-month high of $29.45. The business has a 50 day moving average of $18.29 and a two-hundred day moving average of $19.32. The firm has a market capitalization of $969.63 million, a P/E ratio of -4.41 and a beta of 1.66.
Several equities research analysts have recently weighed in on TBPH shares. Robert W. Baird raised Theravance Biopharma from an “underperform” rating to a “neutral” rating and decreased their target price for the stock from $22.00 to $18.00 in a research report on Wednesday. Cantor Fitzgerald set a $55.00 target price on Theravance Biopharma and gave the stock a “buy” rating in a research report on Friday, August 16th. BidaskClub downgraded Theravance Biopharma from a “sell” rating to a “strong sell” rating in a research report on Friday, October 25th. HC Wainwright started coverage on Theravance Biopharma in a research report on Tuesday, October 29th. They issued a “buy” rating and a $25.00 target price for the company. Finally, Piper Jaffray Companies decreased their target price on Theravance Biopharma from $55.00 to $40.00 and set an “overweight” rating for the company in a research report on Wednesday. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $33.40.
Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines. The company offers VIBATIV, a bactericidal, once-daily injectable antibiotic to treat patients with serious, life-threatening infections due to staphylococcus aureus and other gram-positive bacteria, including methicillin-resistant.
Featured Story: How to read a candlestick chart
Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.